rs1800972 — DEFB1 DEFB1 -44C>G

The Mucosal Shield You Were Born With — and What Happens When It's Thinner

Every mucosal surface in your body — your gut lining, airways, and mouth — faces a constant barrage of bacteria, fungi, and viruses. The front line of defense is not your adaptive immune system with its antibodies and memory cells. It is an older, faster system: human beta-defensin 1 (hBD-1)¹¹ human beta-defensin 1 (hBD-1)
a small cationic antimicrobial peptide, part of the defensin family, that kills bacteria and fungi by disrupting their membranes. Unlike inducible defensins, hBD-1 is constitutively expressed — it is always on, not waiting for infection to be detected. The DEFB1 gene encodes this peptide. The rs1800972 variant sits in the promoter region, 44 bases upstream of the transcription start site, and affects how much hBD-1 your epithelial cells produce around the clock.

The Mechanism

DEFB1 is transcribed from the minus strand of chromosome 8. Papers describe this variant as -44C>G using coding-strand notation: the C (coding strand) becomes a G, which on the plus strand corresponds to a C→G change at position 6,877,901. The GRCh38 plus-strand reference base is C — but C is the minor allele globally (~21.7% frequency). The G allele, present in ~78.3% of people, is the population major allele and is associated with higher constitutive DEFB1 expression.

The -44 position lies within the promoter, in a region that influences transcription factor binding and basal transcriptional activity. Functional studies of salivary hBD-1 protein levels have found that CG heterozygotes produce higher concentrations of hBD-1 than CC homozygotes²² CG heterozygotes produce higher concentrations of hBD-1 than CC homozygotes
Polesello V et al. Impact of DEFB1 gene regulatory polymorphisms on hBD-1 salivary concentration. Arch Oral Biol. 2015, directly linking the G allele to enhanced promoter activity. The CC genotype — two copies of the rare C allele — produces the lowest constitutive hBD-1 output.

At the gut mucosa, reduced hBD-1 is particularly consequential. hBD-1 helps maintain the antimicrobial gradient in the intestinal lumen, controls commensal bacterial overgrowth, and acts as a sentinel against opportunistic pathogens. Impaired constitutive secretion shifts the mucosal equilibrium toward bacterial and fungal permissiveness.

The Evidence

The strongest inflammatory disease association comes from a study of DEFB1 polymorphisms in Crohn's disease³³ study of DEFB1 polymorphisms in Crohn's disease
Kocsis AK et al. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. Scand J Gastroenterol. 2008;43(3):299-307. The GG genotype was dramatically underrepresented among patients compared to controls (4% vs 12%), yielding an odds ratio of 3.367 for protection — equivalent to saying CC homozygotes have approximately 3.4-fold higher risk of colonic Crohn's localization compared to GG carriers.

A large study of 1,101 solid-organ transplant recipients⁴⁴ 1,101 solid-organ transplant recipients
Wójtowicz A et al. IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. J Infect Dis. 2015 Jul 15;212(2):232-41 found rs1800972 significantly associated with both mold colonization (p=0.001) and proven/probable invasive mold infection (p=0.0002), with the association remaining significant in multivariate regression (p=0.01). Mechanistically, C allele carriers showed reduced Aspergillus-induced IL-1β and TNF-α secretion from peripheral blood mononuclear cells, indicating that reduced hBD-1 translates into a blunted early innate response to fungal pathogens — not just a structural barrier deficit.

In chronic periodontitis, an Italian cohort of 155 controls and 439 patients found significant associations between rs1800972 and periodontitis susceptibility⁵⁵ significant associations between rs1800972 and periodontitis susceptibility
Zupin L et al. LTF and DEFB1 polymorphisms are associated with susceptibility toward chronic periodontitis development. Oral Dis. 2017;23(7):882-889. A 2025 study in ankylosing spondylitis found the CG genotype associated with acute anterior uveitis (OR 9.93, 95% CI 1.76–55.7, p=0.009⁶⁶ OR 9.93, 95% CI 1.76–55.7, p=0.009
Fernández-Torres J et al. DEFB1 and NLRP3 gene variants are associated with acute anterior uveitis in ankylosing spondylitis. Int Ophthalmol. 2025), with an interaction identified with NLRP3 rs3806268 suggesting an innate immune signaling axis.

Evidence quality is moderate: studies are predominantly case-control in design, sample sizes vary, and replication across independent cohorts is incomplete for some associations. The invasive mold infection data from the large transplant cohort is the strongest single dataset.

Practical Actions

The actionable consequences of reduced hBD-1 output depend on the biological context. At the gut mucosa, maintaining a dense, diverse microbiome that competes against pathogen colonization provides a functional substitute for impaired defensin output. Fermented foods containing live bacteria (specifically lactobacilli and bifidobacteria associated with mucosal colonization resistance) can reinforce this competitive exclusion.

For people with immunosuppression (transplant recipients, anyone on immunosuppressant medications), the data on invasive mold infection risk warrant proactive discussion with a treating physician about antifungal prophylaxis protocols, as institutional protocols vary and genetic risk can inform thresholds.

At the oral mucosa, the same logic as gut defense applies: antimicrobial augmentation through zinc-containing formulations targets periodontal pathogens directly. The related DEFB1 3'UTR variant rs1047031 provides further context: both promoter and post-transcriptional regulation of hBD-1 can be independently impaired.

Interactions

The DEFB1 locus carries several independently studied variants that affect hBD-1 expression at different regulatory levels. The rs1047031 3'UTR variant reduces hBD-1 through a microRNA-mediated post-transcriptional mechanism — distinct from the promoter-level effect of rs1800972. Individuals carrying risk alleles at both loci may have compound impairment of both transcriptional and post-transcriptional hBD-1 regulation, potentially additive in effect. Similarly, rs11362 (-20G>A) and rs1799946 (-52G>A) are neighboring promoter SNPs studied in the same haplotype context.

The 2025 uveitis study identified an interaction between rs1800972 and NLRP3 rs3806268, suggesting that rs1800972's effect on innate immune signaling extends beyond simple antimicrobial peptide output and involves the inflammasome pathway. This interaction candidate deserves compound action consideration once rs3806268 is in the platform.